LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Slēgts

SektorsVeselības aprūpe

101.29 -0.36

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

100.03

Max

102.55

Galvenie mērījumi
By Trading Economics
Ienākumi	-125M 299M
Pārdošana	141M 1.5B
P/E Sektora vidējais	15.772 110.024
EPS	1.8
Peļņas marža	19.861
Darbinieki	2,844
EBITDA	-92M 415M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+7.34% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.3B 20B
Iepriekšējā atvēršanas cena	101.65
Iepriekšējā slēgšanas cena	101.29

Ziņu noskaņojums

By Acuity

49%

51%

157 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

59.52 / 62.66 Atbalsts un pretestība

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. febr. 17:37 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

2026. g. 20. febr. 16:18 UTC

Galvenie tirgus virzītāji

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

2026. g. 20. febr. 23:12 UTC

Iegādes, apvienošanās, pārņemšana

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

2026. g. 20. febr. 22:12 UTC

Peļņas

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 20. febr. 21:23 UTC

Peļņas

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

2026. g. 20. febr. 21:20 UTC

Tirgus saruna

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

2026. g. 20. febr. 21:01 UTC

Iegādes, apvienošanās, pārņemšana

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

2026. g. 20. febr. 20:38 UTC

Tirgus saruna

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

2026. g. 20. febr. 20:17 UTC

Tirgus saruna

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

2026. g. 20. febr. 20:11 UTC

Tirgus saruna

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

2026. g. 20. febr. 19:59 UTC

Tirgus saruna

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

2026. g. 20. febr. 19:58 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

2026. g. 20. febr. 19:49 UTC

Tirgus saruna

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

2026. g. 20. febr. 19:09 UTC

Tirgus saruna

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

2026. g. 20. febr. 19:00 UTC

Tirgus saruna

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

2026. g. 20. febr. 18:28 UTC

Tirgus saruna

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

2026. g. 20. febr. 18:20 UTC

Tirgus saruna

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

2026. g. 20. febr. 18:05 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 20. febr. 18:04 UTC

Tirgus saruna

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

2026. g. 20. febr. 17:38 UTC

Tirgus saruna

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

2026. g. 20. febr. 17:24 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. febr. 17:24 UTC

Tirgus saruna

Correction to Treasury Yields Fall Market Talk

2026. g. 20. febr. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 20. febr. 16:53 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 20. febr. 16:53 UTC

Tirgus saruna

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

2026. g. 20. febr. 16:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. febr. 16:45 UTC

Tirgus saruna

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

2026. g. 20. febr. 16:40 UTC

Tirgus saruna

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

7.34% augšup

Prognoze 12 mēnešiem

Vidējais 109.2 USD 7.34%

Augstākais 135 USD

Zemākais 73 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

17 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 17 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

157 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation